JNJ-78934804 vs risankizumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: IL-23 p19 · full Ulcerative Colitis pipeline
JNJ-78934804
Developed by Johnson & Johnson
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: August 2028 · NCT07577856 (registry estimate)
No aligned efficacy figure on record for this race.
risankizumab · Skyrizi
Marketed by AbbVie and partners
NCT03398148 · Phase 2/3 · completed
Design meets the 'strong' test: randomized, double-blind (participant and investigator masked), placebo-controlled, large adequately powered sample (n=1555 treated), hard clinical/endoscopic composite endpoint (Adapted Mayo Score remission including endoscopic subscore), and the primary comparison was statistically significant in the favorable direction for all randomized dose arms in both substudies.
Next expected readout: August 2027 · NCT06880744 (registry estimate)
Reported efficacy
clinical remission + endoscopic improvement met (met)
Result source: INSPIRE/COMMAND
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | JNJ-78934804 | risankizumab |
|---|---|---|
| Clinical remission (induction) | —Trial running · NCT07577856 | 20.3% vs 6.2%+14.1 vs placeboNCT033981484 other results
|
| Clinical remission (maintenance) | —Trial running · NCT07577856 | —Trial running · NCT03398135 |
| Clinical response (induction) | —Trial running · NCT07577856 | 64.3% vs 35.7%+28.6 vs placeboNCT033981489 other results
|
| Endoscopic improvement (induction) | —Trial running · NCT07577856 | 36.5% vs 12.1%+24.4 vs placeboNCT03398148 |
| Corticosteroid-free remission (maintenance) | —Trial running · NCT07577856 | —Trial running · NCT03398135 |
Clinical remission (induction)
- JNJ-78934804
- —Trial running · NCT07577856
- risankizumab
- 20.3% vs 6.2%+14.1 vs placeboNCT03398148
4 other results
- 12.4% vs 1.7% NCT03398148
- 9.8% vs 1.7% NCT03398148
- 10.3% vs 1.7% NCT03398148
- 11.5% vs 1.7% NCT03398148
Clinical remission (maintenance)
- JNJ-78934804
- —Trial running · NCT07577856
- risankizumab
- —Trial running · NCT03398135
Clinical response (induction)
- JNJ-78934804
- —Trial running · NCT07577856
- risankizumab
- 64.3% vs 35.7%+28.6 vs placeboNCT03398148
9 other results
- 52.2% vs 30.5% NCT03398148
- 46.2% vs 20% NCT03398148
- 43.5% vs 25% NCT03398148
- 45.9% vs 20% NCT03398148
- 45.9% vs 25% NCT03398148
- 53.4% vs 20% NCT03398148
- 37.9% vs 25% NCT03398148
- 42.6% vs 20% NCT03398148
- 32.8% vs 25% NCT03398148
Endoscopic improvement (induction)
- JNJ-78934804
- —Trial running · NCT07577856
- risankizumab
- 36.5% vs 12.1%+24.4 vs placeboNCT03398148
Corticosteroid-free remission (maintenance)
- JNJ-78934804
- —Trial running · NCT07577856
- risankizumab
- —Trial running · NCT03398135
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
JNJ-78934804: no structured comparison results are available for Ulcerative Colitis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. JNJ-78934804: 0 of 4 rows · risankizumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | risankizumab |
|---|---|
| Dropout rate | 4.9%1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 show 13 more results—1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —360 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —360 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —180 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —180 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1.7%1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 10.3%1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 9.8%600 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 |
| Discontinued due to AEs | 3.3%1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 show 13 more results—1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —360 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —360 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —180 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —180 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 0%1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 2.3%1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 3.3%600 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 |
| Serious AEs | 6.6%1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 show 13 more results2.6%1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1.5%1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 2.3%1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 9.9%360 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1.4%360 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 8.5%180 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 5.6%180 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 8.6%1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 7.3%1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 2.7%1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 8.3%1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 9.7%600 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 |
| Most frequent reported AEs | 1200 mg IV colitis ulcerative 4.9% (placebo 8.5%) headache 4.9% (placebo 5.1%) nasopharyngitis 4.9% (placebo 6.8%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 show 12 more results1200 mg IV covid-19 4.6% (placebo 0%) anaemia 3.2% (placebo 3.4%) headache 2.9% (placebo 5.1%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1200 mg IV covid-19 5.9% (placebo 0%) headache 2.9% (placebo 5.1%) anaemia 1.5% (placebo 3.4%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1200 mg IV covid-19 5.7% (placebo 0%) anaemia 2.9% (placebo 3.4%) colitis ulcerative 1.7% (placebo 8.5%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 360 mg SC nasopharyngitis 8.5% (placebo 6.8%) headache 7% (placebo 5.1%) colitis ulcerative 4.2% (placebo 8.5%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 360 mg SC anaemia 8.5% (placebo 3.4%) covid-19 8.5% (placebo 0%) headache 8.5% (placebo 5.1%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 180 mg SC headache 2.8% (placebo 5.1%) anaemia 1.4% (placebo 3.4%) nasopharyngitis 1.4% (placebo 6.8%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 180 mg SC covid-19 5.6% (placebo 0%) colitis ulcerative 4.2% (placebo 8.5%) anaemia 2.8% (placebo 3.4%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1800 mg IV nasopharyngitis 8.6% (placebo 6.8%) headache 6.9% (placebo 5.1%) anaemia 1.7% (placebo 3.4%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1800 mg IV nasopharyngitis 7% (placebo 6.8%) headache 6.5% (placebo 5.1%) anaemia 3.5% (placebo 3.4%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1800 mg IV nasopharyngitis 10.8% (placebo 6.8%) anaemia 2.7% (placebo 3.4%) colitis ulcerative 2.7% (placebo 8.5%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1800 mg IV dry skin 5.6% (placebo 0%) headache 5.6% (placebo 5.1%) nasopharyngitis 5.6% (placebo 6.8%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 600 mg IV nasopharyngitis 8.1% (placebo 6.8%) bronchitis 6.5% (placebo 0%) dry skin 3.2% (placebo 0%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
risankizumab
show 4 more results
show 3 more results
show 9 more results
show 4 more results
show 3 more results
show 3 more results
show 3 more results
show 4 more results
show 3 more results
show 3 more results
show 4 more results
show 3 more results
+ 8 further endpoints in the CSV export.
Crohn's Disease
Shared mechanism: IL-23 p19 · full Crohn's Disease pipeline
JNJ-78934804
Developed by Johnson & Johnson
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2028 · NCT07577843 (registry estimate)
No aligned efficacy figure on record for this race.
risankizumab · Skyrizi
Marketed by AbbVie and partners
NCT03104413 · Phase 3 · completed
Design meets the 'strong' test: randomized, double-blind, placebo-controlled, adequately powered (n~600), with a hard endoscopic co-primary endpoint (SES-CD response) plus CDAI clinical remission, and both primary endpoint comparisons were statistically significant in the favorable direction for both doses vs placebo.
Next expected readout: March 2027 · NCT06063967 (registry estimate)
Reported efficacy
US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission (Week 12); US Specific: Percentage of Participants With Endoscopic Response (Week 12); Global Outside of US: Percentage of Participants With Clinical Remission (Week 12); Global Outside of US: Percentage of Participants With Endoscopic Response (Week 12): US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission (Week 12): Placebo (Induction Period 1) 19.8% (95% CI 14.1-25.5) vs Risankizumab 600mg (Induction Period 1) 42.0% (95% CI 34.9-49.0) vs Risankizumab 1200mg (Induction Period 1) 40.3% (95% CI 33.4-47.3); p=<0.001 (Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1)), p=< 0.001 (Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1)) (met)
Result source: NCT03104413
Results for Crohn's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | JNJ-78934804 | risankizumab |
|---|---|---|
| Clinical remission (induction) | —Trial running · NCT07577843 | 42% vs 19.8%+22.2 vs placeboNCT0310441326 other results
|
| Endoscopic response (induction) | —Trial running · NCT07577843 | 28.8% vs 11.2%+17.6 vs placeboNCT0310441310 other results
|
| Clinical remission (maintenance) | —Trial running · NCT07577843 | —Trial running · NCT06063967 |
| Endoscopic response (maintenance) | —Trial running · NCT07577843 | —Trial running · NCT06063967 |
Clinical remission (induction)
- JNJ-78934804
- —Trial running · NCT07577843
- risankizumab
- 42% vs 19.8%+22.2 vs placeboNCT03104413
26 other results
- 28.8% vs 11.2% NCT03104413
- 45.2% vs 24.6% NCT03105128
- 43.5% vs 21.7% NCT03105128
- 40.3% vs 19.8% NCT03104413
- 34.2% vs 11.2% NCT03104413
- 41.6% vs 24.6% NCT03105128
- 41% vs 21.7% NCT03105128
- 34.6% vs 19.3% NCT03104413
- 42% vs 19.8% NCT03104413
- 43.5% vs 21.7% NCT03105128
- 45.2% vs 24.6% NCT03105128
- 20.9% vs 11.2% NCT03104413
- 17.3% vs 8% NCT03104413
- 18.4% vs 10.3% NCT03105128
- 21% vs 9.1% NCT03105128
- 39.8% vs 19.3% NCT03104413
- 40.3% vs 19.8% NCT03104413
- 41% vs 21.7% NCT03105128
- 41.6% vs 24.6% NCT03105128
- 19.4% vs 11.2% NCT03104413
- 18.3% vs 8% NCT03104413
- 18.9% vs 10.3% NCT03105128
- 21.2% vs 9.1% NCT03105128
- 36.6% vs 15.4% NCT02031276
- 28% vs 15.4% NCT02031276
- 19.5% vs 15.4% NCT02031276
Endoscopic response (induction)
- JNJ-78934804
- —Trial running · NCT07577843
- risankizumab
- 28.8% vs 11.2%+17.6 vs placeboNCT03104413
10 other results
- 34.6% vs 19.3% NCT03104413
- 40.3% vs 12% NCT03105128
- 40.3% vs 12% NCT03105128
- 34.2% vs 11.2% NCT03104413
- 39.8% vs 19.3% NCT03104413
- 32.1% vs 12% NCT03105128
- 32.1% vs 12% NCT03105128
- 36.6% vs 12.8% NCT02031276
- 31.7% vs 12.8% NCT02031276
- 26.8% vs 12.8% NCT02031276
Clinical remission (maintenance)
- JNJ-78934804
- —Trial running · NCT07577843
- risankizumab
- —Trial running · NCT06063967
Endoscopic response (maintenance)
- JNJ-78934804
- —Trial running · NCT07577843
- risankizumab
- —Trial running · NCT06063967
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
JNJ-78934804: no structured comparison results are available for Crohn's Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. JNJ-78934804: 0 of 4 rows · risankizumab: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | risankizumab |
|---|---|
| Dropout rate | 1.9%600 mga NCT03104413 · Phase 3 · Crohn's Disease · phase 3 show 16 more results—360 mg NCT03104413 · Phase 3 · Crohn's Disease · phase 3 —180 mg NCT03104413 · Phase 3 · Crohn's Disease · phase 3 2.9%1200 mg NCT03104413 · Phase 3 · Crohn's Disease · phase 3 —1200 mg NCT03104413 · Phase 3 · Crohn's Disease · phase 3 —600mg IV NCT03105128 · Phase 3 · Crohn's Disease · phase 3 —360mg SC NCT03105128 · Phase 3 · Crohn's Disease · phase 3 —180mg SC NCT03105128 · Phase 3 · Crohn's Disease · phase 3 —1200mg IV NCT03105128 · Phase 3 · Crohn's Disease · phase 3 —1200mg IV NCT03105128 · Phase 3 · Crohn's Disease · phase 3 —1200mg IV NCT03105128 · Phase 3 · Crohn's Disease · phase 3 —600 mg IV NCT02513459 · Phase 2 · registry result, not featured evidence —180 mg SC NCT02513459 · Phase 2 · registry result, not featured evidence —600 mg IV NCT02031276 · Phase 2 · registry result, not featured evidence —600 mg IV NCT02031276 · Phase 2 · registry result, not featured evidence —180 mg SC NCT02031276 · Phase 2 · registry result, not featured evidence —200 mg IV NCT02031276 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —600 mga NCT03104413 · Phase 3 · Crohn's Disease · phase 3 show 16 more results—360 mg NCT03104413 · Phase 3 · Crohn's Disease · phase 3 —180 mg NCT03104413 · Phase 3 · Crohn's Disease · phase 3 —1200 mg NCT03104413 · Phase 3 · Crohn's Disease · phase 3 —1200 mg NCT03104413 · Phase 3 · Crohn's Disease · phase 3 —600mg IV NCT03105128 · Phase 3 · Crohn's Disease · phase 3 —360mg SC NCT03105128 · Phase 3 · Crohn's Disease · phase 3 —180mg SC NCT03105128 · Phase 3 · Crohn's Disease · phase 3 —1200mg IV NCT03105128 · Phase 3 · Crohn's Disease · phase 3 —1200mg IV NCT03105128 · Phase 3 · Crohn's Disease · phase 3 —1200mg IV NCT03105128 · Phase 3 · Crohn's Disease · phase 3 —600 mg IV NCT02513459 · Phase 2 · registry result, not featured evidence —180 mg SC NCT02513459 · Phase 2 · registry result, not featured evidence —600 mg IV NCT02031276 · Phase 2 · registry result, not featured evidence —600 mg IV NCT02031276 · Phase 2 · registry result, not featured evidence —180 mg SC NCT02031276 · Phase 2 · registry result, not featured evidence —200 mg IV NCT02031276 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 4.9%600 mga NCT03104413 · Phase 3 · Crohn's Disease · phase 3 show 16 more results4.8%360 mg NCT03104413 · Phase 3 · Crohn's Disease · phase 3 4.9%180 mg NCT03104413 · Phase 3 · Crohn's Disease · phase 3 4.4%1200 mg NCT03104413 · Phase 3 · Crohn's Disease · phase 3 7.1%1200 mg NCT03104413 · Phase 3 · Crohn's Disease · phase 3 7.2%600mg IV NCT03105128 · Phase 3 · Crohn's Disease · phase 3 4.4%360mg SC NCT03105128 · Phase 3 · Crohn's Disease · phase 3 4.5%180mg SC NCT03105128 · Phase 3 · Crohn's Disease · phase 3 3.8%1200mg IV NCT03105128 · Phase 3 · Crohn's Disease · phase 3 5.3%1200mg IV NCT03105128 · Phase 3 · Crohn's Disease · phase 3 6%1200mg IV NCT03105128 · Phase 3 · Crohn's Disease · phase 3 0%600 mg IV NCT02513459 · Phase 2 · registry result, not featured evidence 35.4%180 mg SC NCT02513459 · Phase 2 · registry result, not featured evidence 9.8%600 mg IV NCT02031276 · Phase 2 · registry result, not featured evidence 10.9%600 mg IV NCT02031276 · Phase 2 · registry result, not featured evidence 11.3%180 mg SC NCT02031276 · Phase 2 · registry result, not featured evidence 24.4%200 mg IV NCT02031276 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 600 mga headache 5.3% (placebo 5.3%) arthralgia 3.9% (placebo 3.9%) nasopharyngitis 3.9% (placebo 5.3%) NCT03104413 · Phase 3 · Crohn's Disease · phase 3 show 16 more results360 mg arthralgia 2.4% (placebo 3.9%) headache 2.4% (placebo 5.3%) nausea 2.4% (placebo 4.8%) NCT03104413 · Phase 3 · Crohn's Disease · phase 3 180 mg arthralgia 4.9% (placebo 3.9%) crohn's disease 2.4% (placebo 6.3%) headache 2.4% (placebo 5.3%) NCT03104413 · Phase 3 · Crohn's Disease · phase 3 1200 mg headache 4.9% (placebo 5.3%) arthralgia 4.4% (placebo 3.9%) nasopharyngitis 3.9% (placebo 5.3%) NCT03104413 · Phase 3 · Crohn's Disease · phase 3 1200 mg headache 7.1% (placebo 5.3%) nausea 7.1% (placebo 4.8%) crohn's disease 4.8% (placebo 6.3%) NCT03104413 · Phase 3 · Crohn's Disease · phase 3 600mg IV headache 6.4% (placebo 4.3%) nasopharyngitis 5.9% (placebo 2.7%) nausea 4.3% (placebo 5.4%) NCT03105128 · Phase 3 · Crohn's Disease · phase 3 360mg SC headache 4.4% (placebo 4.3%) anaemia 2.9% (placebo 2.7%) crohn's disease 1.5% (placebo 5.4%) NCT03105128 · Phase 3 · Crohn's Disease · phase 3 180mg SC crohn's disease 3% (placebo 5.4%) headache 1.5% (placebo 4.3%) nasopharyngitis 1.5% (placebo 2.7%) NCT03105128 · Phase 3 · Crohn's Disease · phase 3 1200mg IV nasopharyngitis 5.9% (placebo 2.7%) headache 5.4% (placebo 4.3%) nausea 3.5% (placebo 5.4%) NCT03105128 · Phase 3 · Crohn's Disease · phase 3 1200mg IV headache 6.6% (placebo 4.3%) anaemia 5.3% (placebo 2.7%) nausea 3.9% (placebo 5.4%) NCT03105128 · Phase 3 · Crohn's Disease · phase 3 1200mg IV headache 3% (placebo 4.3%) anaemia 1.5% (placebo 2.7%) nasopharyngitis 1.5% (placebo 2.7%) NCT03105128 · Phase 3 · Crohn's Disease · phase 3 600 mg IV abdominal pain upper 25% ear pain 25% haematochezia 25% NCT02513459 · Phase 2 · registry result, not featured evidence 180 mg SC nasopharyngitis 30.8% gastroenteritis 23.1% fatigue 20% NCT02513459 · Phase 2 · registry result, not featured evidence 600 mg IV arthralgia 19.5% (placebo 10.3%) headache 12.2% (placebo 12.8%) abdominal pain 9.8% (placebo 12.8%) NCT02031276 · Phase 2 · registry result, not featured evidence 600 mg IV abdominal pain 10.9% (placebo 12.8%) nasopharyngitis 7.9% (placebo 7.7%) arthralgia 6.9% (placebo 10.3%) NCT02031276 · Phase 2 · registry result, not featured evidence 180 mg SC nasopharyngitis 14.5% (placebo 7.7%) arthralgia 9.7% (placebo 10.3%) headache 9.7% (placebo 12.8%) NCT02031276 · Phase 2 · registry result, not featured evidence 200 mg IV nausea 22% (placebo 10.3%) abdominal pain 14.6% (placebo 12.8%) arthralgia 14.6% (placebo 10.3%) NCT02031276 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 6 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
risankizumab
show 26 more results
show 10 more results
show 15 more results
show 3 more results
show 3 more results
show 3 more results
show 10 more results
show 15 more results
show 7 more results
show 7 more results
show 7 more results
show 7 more results
+ 32 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: JNJ-78934804's landscape · risankizumab's landscape